临床试验/NCT04397003

NCT04397003进行中（未招募）2 期

Phase II Study of a Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

Washington University School of Medicine1 个研究点分布在 1 个国家目标入组 6 人开始时间: 2022年3月30日最近更新: 2025年10月22日

适应症

干预措施

试验速览

阶段: 2 期
状态: 进行中（未招募）
发起方: Washington University School of Medicine
入组人数: 6
试验地点: 1
主要终点: Safety and tolerability of the combination of durvalumab and a neoantigen vaccine as measured by number of participants experiencing adverse events

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The investigators hypothesize that a personalized neoantigen vaccine combined with durvalumab will improve the progression free survival of patients with extensive state small cell lung cancer (ES-SCLC).

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC)
•Considered suitable to receive a platinum-based chemotherapy regimen with durvalumab as 1st line treatment for ES-SCLC.
•Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan, as ≥ 20 mm by chest x-ray, or ≥ 10 mm with calipers by clinical exam.
•At least one lesion must be able to be biopsied at the time of enrollment. The site utilized for biopsy cannot be utilized as a target lesion for efficacy measurement.
•At least 18 years of age.
•ECOG performance status ≤ 1
•Life expectancy of at least 12 weeks.
•Body weight > 30 kg.
•Adequate normal organ and marrow function as defined below:
•Hemoglobin ≥ 9.0 g/dL
•Absolute neutrophil count ≥ 1.0 K/cumm
•Platelet count ≥ 75 K/cumm
•Serum bilirubin ≤ 1.5 x institutional upper limit of normal (IULN)
•AST (SGOT)/ALT (SGPT) ≤ 2.5 x IULN unless liver metastases are present, in which case it must be ≤ 5 x IULN
•Measured creatinine clearance > 40 mL/min or calculated creatinine clearance > 40 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance
•Adequate cardiac function defined as QTcF < 470 ms on 12-lead ECG.
•Baseline pulse oximetry must be > 92% on room air.
•Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
•Women < 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
•Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, had chemotherapy-induced menopause with last menses > 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy):
•Male and female patients of reproductive potential must be willing to employ effective birth control from screening to 90 days after the last dose of durvalumab
•Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable). This includes consent for tumor/normal exome sequencing and dbGaP-based data sharing.

排除标准

•Prior treatment with a PD-1 or PD-L1 inhibitor (including durvalumab).
•A history of other primary malignancy except for:
•Malignancy treated with curative intent and with no know active disease ≥ 5 years before the first dose of study drug and of low potential risk for recurrence
•Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
•Adequately treated carcinoma in situ without evidence of disease
•Currently receiving any other investigational agents.
•Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
•Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment.
•Any unresolved toxicity NCI CTCAE grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.
•Patients with grade ≥ 2 neuropathy will be evaluated on a case-by-case basis after consultation with the PI.
•Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the PI.
•Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.
•Major surgical procedure (as defined by the PI) within 28 days prior to the first dose of study drug. Note: local surgery of isolated lesions for palliative intent is acceptable.
•History of allogenic organ transplantation.
•History of leptomeningeal carcinomatosis.
•Any known history of brain metastases. Patients with known brain metastases must be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
•A history of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab or other agents used in the study.
•Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty.
•Uncontrolled intercurrent illness including, but not limited to:
•uncontrolled ongoing or active infection
•a history of myocarditis or congestive heart failure (as defined by New York Heart Association Functional Classification III or IV)
•myocardial infarction 6 months prior to study entry
•uncontrolled hypertension
•unstable angina pectoris
•serious uncontrolled cardiac arrhythmia
•interstitial lung disease (ILD) or a history of ILD/pneumonitis requiring treatment with systemic steriods
•serious chronic gastrointestinal conditions associated with diarrhea
•psychiatric illness or social situations that would limit compliance with study requirements, substantially increase the risk of incurring AEs, or compromise the ability of the patient to give written informed consent.
•Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
•Intranasal, inhaled, topical steroids, or local steroid injections (e.g. intra-articular injection)
•Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
•Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication)
•Receipt of live attenuated vaccine within 30 days prior to the first dose of study drug. Note: patients, if enrolled, should not receive live vaccine whilst receiving study drug and up to 30 days after the last dose of study drug.
•History of syncopal or vasovagal episode as determined by medical record and history in the 12 month period prior to enrollment
•Less than 2 acceptable potential injection sites for IM injection and electroporation considering the left and right medial deltoid, and anterolateral quadriceps muscles. A site for injection and electroporation is not acceptable if there is inadequate muscle mass to support at least a 19 mm /0.75 inch injection depth or a skin pinch thickness measurement of >50 mm as assessed using the provided caliper). Eligible injection sites must also have intact lymphoid drainage and be free from tattoos, hypertrophic skin patches, keloids or other skin conditions which could interfere with the administration procedure or subsequent assessment of local reactogenicity. Note: In order to ensure adequate muscle mass for administrations for participants with a weight <65 kg, potentially eligible administration sites are confined to the outer aspect of the upper thigh (left or right vastus lateralis muscle). The left and right medial deltoid are not eligible administration sites for those participants.
•Is an individual in whom the ability to observe possible local site reactions at >2 eligible injection sites (left and right medial deltoid or left and right vastus lateralis muscles) is, in the opinion of the investigator, unacceptably obscured due to a physical condition.
•Has a metal implant or implantable device within the area of the electroporation injection site at >2 of the eligible injection sites.
•Contraindication to intramuscular injections and/or blood draws.
•Any chronic or active neurologic disorder, including seizures and epilepsy, excluding a single febrile seizure as a child.
•Current use of any non-removable electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators.
•Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g. colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]. The following are exceptions to this criterion:
•Patients with vitiligo or alopecia
•Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement
•Any chronic skin condition that does not require systemic therapy
•Patients without active disease in the last 5 years may be included but only after consultation with the study physician
•Patients with celiac disease controlled by diet alone
•Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
•History of primary active immunodeficiency.
•Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
•Reconfirmation of Eligibility Prior to Administration of Neoantigen DNA Vaccine:
另有 13 项未显示

研究组 & 干预措施

Neoantigen DNA vaccine+durvalumab

Experimental

Patients will receive durvalumab (1500mg Q3W) in combination with standard of care carboplatin and etoposide for a total of 4 cycles given every 3 weeks
Beginning 4 weeks following Cycle 4 of carboplatin/etoposide/durvalumab, patients on will then receive 6 cycles of durvalumab 1500 mg with the polyepitope neoantigen DNA vaccine, both administered once every 4 weeks
Patients may then receive durvalumab every 4 weeks until disease progression or drug toxicity
Should a delay in vaccine preparation occur, patients will begin durvalumab and the vaccine will be added with the subsequent cycle.

干预措施: Neoantigen DNA vaccine (Biological)

Neoantigen DNA vaccine+durvalumab

Experimental

Patients will receive durvalumab (1500mg Q3W) in combination with standard of care carboplatin and etoposide for a total of 4 cycles given every 3 weeks
Beginning 4 weeks following Cycle 4 of carboplatin/etoposide/durvalumab, patients on will then receive 6 cycles of durvalumab 1500 mg with the polyepitope neoantigen DNA vaccine, both administered once every 4 weeks
Patients may then receive durvalumab every 4 weeks until disease progression or drug toxicity
Should a delay in vaccine preparation occur, patients will begin durvalumab and the vaccine will be added with the subsequent cycle.

干预措施: Durvalumab (Drug)

Neoantigen DNA vaccine+durvalumab

Experimental

Patients will receive durvalumab (1500mg Q3W) in combination with standard of care carboplatin and etoposide for a total of 4 cycles given every 3 weeks
Beginning 4 weeks following Cycle 4 of carboplatin/etoposide/durvalumab, patients on will then receive 6 cycles of durvalumab 1500 mg with the polyepitope neoantigen DNA vaccine, both administered once every 4 weeks
Patients may then receive durvalumab every 4 weeks until disease progression or drug toxicity
Should a delay in vaccine preparation occur, patients will begin durvalumab and the vaccine will be added with the subsequent cycle.

干预措施: TDS-IM v2.0 Device (Device)

Neoantigen DNA vaccine+durvalumab

Experimental

Patients will receive durvalumab (1500mg Q3W) in combination with standard of care carboplatin and etoposide for a total of 4 cycles given every 3 weeks
Beginning 4 weeks following Cycle 4 of carboplatin/etoposide/durvalumab, patients on will then receive 6 cycles of durvalumab 1500 mg with the polyepitope neoantigen DNA vaccine, both administered once every 4 weeks
Patients may then receive durvalumab every 4 weeks until disease progression or drug toxicity
Should a delay in vaccine preparation occur, patients will begin durvalumab and the vaccine will be added with the subsequent cycle.

干预措施: Peripheral blood draws (Procedure)

结局指标

主要结局

Safety and tolerability of the combination of durvalumab and a neoantigen vaccine as measured by number of participants experiencing adverse events

时间窗: Through 90 days after completion of treatment (estimated to be 2 years and 3 months)

-Safety and tolerability will be measured by National Cancer Institute Common Terminology Criteria (NCI CTCAE) v 5.0

Feasibility of combining durvalumab with a neoantigen vaccine as measured by the number of participants that had a vaccine produced for them

时间窗: Within 24 weeks of the start of consolidation durvalumab

-Feasibility is defined as the ability to produce a vaccine for 80% of patients enrolled within 24 weeks of the start of consolidation durvalumab.

次要结局

Overall survival (OS)(Through completion of follow-up (estimated to be 4 years and 3 months))
Progression-free survival (PFS)(12 months)
Response conversion rate(Through completion of treatment (estimated to be 2 years))
Duration of response (DOR)(Through completion of treatment (estimated to be 2 years))

研究者

发起方

Washington University School of Medicine

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

进行中（未招募）

1 期

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaCutaneous Melanoma

NCT03929029Dana-Farber Cancer Institute11

已完成

1 期

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in MelanomaMelanoma

NCT01970358Patrick Ott, MD, PhD15

招募中

1 期

NCT05269381Mayo Clinic138

已完成

1 期

Personalized Neoantigen Cancer Vaccine for Patients With Solid TumorsSolid Tumor, AdultCancer

NCT06614140Seqker Biosciences, Inc.8

进行中（未招募）

1 期

NeoVax Plus Ipilimumab in Renal Cell CarcinomaKidney Cancer

NCT02950766Patrick Ott, MD, PhD19